SLC5A2 and COVID-19: Hence, these underlying conditions and further meta-analyses suggest the potential beneficial effects of SGLT2 inhibitor treatment to reduce acute and long-term COVID-19 mortality risk in the general population and in those with metabolic diseases [74,82,83].